Soleno Therapeutics, Inc. $SLNO Shares Acquired by JPMorgan Chase & Co.

JPMorgan Chase & Co. lifted its position in Soleno Therapeutics, Inc. (NASDAQ:SLNO) by 52.8% during the 3rd quarter, Holdings Channel.com reports. The fund owned 407,444 shares of the company’s stock after acquiring an additional 140,779 shares during the period. JPMorgan Chase & Co.’s holdings in Soleno Therapeutics were worth $27,543,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in SLNO. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its stake in Soleno Therapeutics by 1.1% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 17,360 shares of the company’s stock valued at $1,242,000 after purchasing an additional 189 shares during the last quarter. Goldman Sachs Group Inc. lifted its holdings in shares of Soleno Therapeutics by 50.9% during the first quarter. Goldman Sachs Group Inc. now owns 633,110 shares of the company’s stock worth $45,236,000 after purchasing an additional 213,667 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its position in Soleno Therapeutics by 48.0% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 40,715 shares of the company’s stock valued at $2,909,000 after buying an additional 13,211 shares during the last quarter. Nisa Investment Advisors LLC increased its holdings in Soleno Therapeutics by 287.8% in the 2nd quarter. Nisa Investment Advisors LLC now owns 539 shares of the company’s stock worth $45,000 after buying an additional 400 shares during the period. Finally, Envestnet Asset Management Inc. increased its holdings in Soleno Therapeutics by 32.9% in the 2nd quarter. Envestnet Asset Management Inc. now owns 5,866 shares of the company’s stock worth $491,000 after buying an additional 1,453 shares during the period. Hedge funds and other institutional investors own 97.42% of the company’s stock.

Analyst Ratings Changes

Several analysts have commented on SLNO shares. Wall Street Zen cut shares of Soleno Therapeutics from a “buy” rating to a “hold” rating in a research note on Saturday. Robert W. Baird set a $107.00 target price on shares of Soleno Therapeutics in a research report on Tuesday, January 13th. Zacks Research downgraded Soleno Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, February 3rd. Wolfe Research set a $60.00 price objective on Soleno Therapeutics in a research note on Monday, January 12th. Finally, Wells Fargo & Company decreased their price objective on Soleno Therapeutics from $114.00 to $110.00 and set an “overweight” rating for the company in a report on Friday. One equities research analyst has rated the stock with a Strong Buy rating, twelve have issued a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $108.38.

Key Stories Impacting Soleno Therapeutics

Here are the key news stories impacting Soleno Therapeutics this week:

• Positive Sentiment: Earnings beat and profitability: Soleno reported Q4 2025 EPS of $0.80 (vs. $0.64 consensus) and revenue of $91.73M (vs. $88.55M), and management highlighted achieving profitability — the core reason investors are bidding the stock up. Soleno Therapeutics, Inc. Q4 2025 Earnings Call Summary
• Neutral Sentiment: Full earnings/transcript availability: Multiple transcripts and call write-ups (Seeking Alpha, Yahoo) give investors detailed color on guidance, margins and cash flow — useful for conviction but not immediate catalysts. Q4 2025 Earnings Call Transcript Q4 2025 Earnings Call Highlights
• Neutral Sentiment: Wells Fargo cut its price target slightly from $114 to $110 but kept an Overweight rating — this is a modest headwind but still signals strong upside from analysts. Wells Fargo price-target note
• Negative Sentiment: TD Cowen substantially lowered its target (from $120 to $85) despite maintaining a Buy rating — the larger cut adds downward pressure to headline analyst sentiment and may temper the rally. TD Cowen price-target change
• Negative Sentiment: Near-term volatility / profit-taking explained: Coverage and commentary note a sharp intraday decline (reported as ~10.8% in one write-up) after the earnings run-up — investors appear to be re‑rating the name on guidance details, forward EPS expectations, and valuation. Why SLNO Stock Is Down 10.80%

Soleno Therapeutics Stock Performance

NASDAQ SLNO opened at $39.07 on Friday. The stock has a market capitalization of $2.02 billion, a price-to-earnings ratio of 169.88 and a beta of -3.16. The stock has a 50-day moving average of $42.63 and a 200 day moving average of $53.33. The company has a current ratio of 16.08, a quick ratio of 15.88 and a debt-to-equity ratio of 0.10. Soleno Therapeutics, Inc. has a twelve month low of $32.63 and a twelve month high of $90.32.

Soleno Therapeutics (NASDAQ:SLNO) last posted its quarterly earnings data on Wednesday, February 25th. The company reported $0.80 EPS for the quarter, beating analysts’ consensus estimates of $0.64 by $0.16. The business had revenue of $91.73 million during the quarter, compared to analysts’ expectations of $88.55 million. Sell-side analysts anticipate that Soleno Therapeutics, Inc. will post -3.72 EPS for the current fiscal year.

About Soleno Therapeutics

Soleno Therapeutics, Inc is a clinical‐stage biopharmaceutical company focused on the development and commercialization of therapies for rare and orphan diseases. Headquartered in Redwood City, California, Soleno leverages a precision medicine approach to identify and advance small‐molecule treatments that address underlying genetic and metabolic dysfunctions. The company’s scientific strategy centers on repurposing and reformulating existing compounds to maximize therapeutic benefit in underserved patient populations.

The company’s lead candidate, diazoxide choline controlled release (DCCR), is being investigated for the treatment of Prader-Willi syndrome (PWS), a complex neurodevelopmental disorder characterized by insatiable appetite, hormonal imbalances and behavioral challenges.